Featured Research

from universities, journals, and other organizations

New Predictor For Lung Cancer Treatment And Survival Announced

Date:
June 6, 2006
Source:
University Hospitals of Cleveland
Summary:
Research has found a promising, novel biomarker that may be used to predict the survival of patients with advanced lung cancer and their response to treatment. Patients with a low level of the biomarker ICAM had a better chance of survival and an increased response to chemotherapy.

Dr. Dowlati found that patients with a low level of the biomarker ICAM had a better chance of survival and an increased response to chemotherapy. Dr. Dowlati analyzed data from a major national study, released at ASCO in 2005, that found the monoclonal antibody Bevacizumab (Avastin), in addition to standard therapy, was more effective than standard treatment alone for patients with advanced, non-squamous non-small cell lung cancer.

Related Articles


h a low level of the biomarker ICAM had a better chance of survival and an increased response to chemotherapy. Dr. Dowlati analyzed data from a major national study, released at ASCO in 2005, that found the monoclonal antibody Bevacizumab (Avastin), in addition to standard therapy, was more effective than standard treatment alone for patients with advanced, non-squamous non-small cell lung cancer.

The analysis indicated that patients with low levels of ICAM (intercellular adhesion molecule -1), had a higher response rate to treatment (29% versus 13%) than patients with high ICAM levels. Patients with low ICAM levels also had a significantly better overall survival rate.

"We believe this research confirms a significant new prognostic marker in lung cancer," says Dr. Dowlati, who is also assistant professor at Case Western Reserve University School of Medicine. "Previously, it has been a challenge to identify those patients that will respond best to treatment and what their outcomes will be. This biomarker appears to serve as a much better predictor than gender, patients' overall health and sites of metastases." These findings confirm a pilot study performed three years ago at Ireland Cancer Center by Drs. Dowlati, Scot Remick and Keith McCrae, an expert in blood vessel disorders found in cancer.

Data was analyzed from a phase III study, conducted by the Eastern Cooperative Oncology Group (ECOG), which involved 878 patients nationwide who were randomized to standard chemotherapy - paclitaxel and carboplatin - with and without Bevacizumab. Patients who received Bevacizumab lived 2.5 months longer and had a 24.8% shrinkage in their tumors versus 9.4% shrinkage in patients who had chemotherapy alone. Bevacizumab is an anti-angiogenesis inhibitor designed to prevent the formation of new blood vessels to the tumor.

"This represents a major step forward in treating patients with advanced lung cancer," says Stanton Gerson, MD, Director of the Ireland Cancer Center and the Case Comprehensive Cancer Center. "This biomarker may help clinicians identify patients who are candidates for treatment and who will benefit from it. This finding is likely to be useful in other cancers as well."

Lung cancer is the second most commonly diagnosed cancer and is the leading cause of cancer-related death in both men and women in this country. An estimated 163,510 deaths from lung cancer occurred in 2005 in the United States, accounting for about 29 percent of all cancer-related deaths in the nation.

Other significant presentations at ASCO by Ireland Cancer Center physicians include:

  • Scot Remick, MD, presented an update to a Phase II clinical trial evaluating Ca4P (combretastatin) as a treatment for advanced anaplastic thyroid cancer. Ireland researchers found that 29% of patients experienced stability of their aggressive cancer with this anti-angiogenesis inhibitor. "Without a doubt, we have observed patient benefit from Combretastain therapy in anaplastic thyroid cancer, which is one of the most aggressive types of cancer," says Dr. Remick, Associate Director for Clinical Research at Ireland and Professor of Medicine at Case. "In some cases, patient response has been extraordinary, and supportive of the complete response observed in one patient who is still cancer free today--more than six years after participating in our initial Phase I clinical trial. We believe that the data presented today provides further evidence of the biological activity of this compound and that additional clinical trials are warranted to investigate the potential clinical benefit of combining Combretastatin with other therapies, including chemotherapy."
  • Janice Lyons, MD, on behalf of the breast cancer team of the Ireland Cancer Center, presented findings that the use of traditional chemotherapy, docetaxel, with bevacizumab (Avastin) is well tolerated in patients with locally advanced breast cancer. This Phase II study analyzed docetaxel alone compared with its use in combination with bevacizumab and found no significant differences in side effects between the two groups.
  • Panos Savvides, MD, on behalf of the head and neck cancer team of the Ireland Cancer Center, presented findings from a Phase I study of the use of Tarceva in combination with docetaxel in successfully treating advanced head and neck cancers. This promising research will be followed up by a Phase II study into the efficacy of Tarceva, an EGFR tyrosine kinase inhibitor.
  • Along with colleagues at the University of Nairobi and the Uganda Cancer Institute, Dr. Remick presented findings that oral chemotherapy is effective in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa. In a resource-limited setting where the use of intravenous treatment is challenging, the use of oral medications has comparable outcomes to its use in the United States.

Story Source:

The above story is based on materials provided by University Hospitals of Cleveland. Note: Materials may be edited for content and length.


Cite This Page:

University Hospitals of Cleveland. "New Predictor For Lung Cancer Treatment And Survival Announced." ScienceDaily. ScienceDaily, 6 June 2006. <www.sciencedaily.com/releases/2006/06/060606091652.htm>.
University Hospitals of Cleveland. (2006, June 6). New Predictor For Lung Cancer Treatment And Survival Announced. ScienceDaily. Retrieved December 20, 2014 from www.sciencedaily.com/releases/2006/06/060606091652.htm
University Hospitals of Cleveland. "New Predictor For Lung Cancer Treatment And Survival Announced." ScienceDaily. www.sciencedaily.com/releases/2006/06/060606091652.htm (accessed December 20, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, December 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Best Tips to Curb Holiday Carbs

The Best Tips to Curb Holiday Carbs

Buzz60 (Dec. 19, 2014) It's hard to resist those delicious but fattening carbs we all crave during the winter months, but there are some ways to stay satisfied without consuming the extra calories. Vanessa Freeman (@VanessaFreeTV) has the details. Video provided by Buzz60
Powered by NewsLook.com
Sierra Leone Bikers Spread the Message to Fight Ebola

Sierra Leone Bikers Spread the Message to Fight Ebola

AFP (Dec. 19, 2014) More than 100 motorcyclists hit the road to spread awareness messages about Ebola. Nearly 7,000 people have now died from the virus, almost all of them in west Africa, according to the World Health Organization. Video provided by AFP
Powered by NewsLook.com
Researchers Test Colombian Village With High Alzheimer's Rates

Researchers Test Colombian Village With High Alzheimer's Rates

AFP (Dec. 19, 2014) In Yarumal, a village in N. Colombia, Alzheimer's has ravaged a disproportionately large number of families. A genetic "curse" that may pave the way for research on how to treat the disease that claims a new victim every four seconds. Duration: 02:42 Video provided by AFP
Powered by NewsLook.com
Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Double-Amputee Becomes First To Move Two Prosthetic Arms With His Mind

Buzz60 (Dec. 19, 2014) A double-amputee makes history by becoming the first person to wear and operate two prosthetic arms using only his mind. Jen Markham has the story. Video provided by Buzz60
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins